Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Although the main focus of immuno-oncology has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumour reduction and elimination. Tumour-associated macrophages often have net pro-tumour effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumours. Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associated macrophages have had some success. We hypothesized that pharmacologic modulation of macrophage phenotype could produce an anti-tumour effect. We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes. TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumours. Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumour reduction. These data introduce class IIa HDAC inhibition as a means to harness the anti-tumour potential of macrophages to enhance cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylase inhibitor, TMP195, polarizes TAMs toward an anti‐tumor phenotype and increases the efficacy of carboplatin, paclitaxel, and anti‐PD‐1 therapies [84].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
Self-citation
Research works printed but not linked: 2
- DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL & Coussens LM Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery 1, 54– 67, 10.1158/2159-8274.cd-10-0028 (2011). 22039576 PMC3203524 · DOI · Paper page
- Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ & Immunological Genome Project C Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature immunology 13, 499– 510, 10.1038/ni.2262 (2012). 22466668 PMC3366863 · DOI · Paper page
Cited by
Items 301–400 of 568
Alveolar macrophages in lung cancer: opportunities and challenges
Chang, C.-Y., Armstrong, D., Corry, D. B., & Kheradmand, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1268939 · Cited by 30
Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation
Trotta, R., Rivis, S., Zhao, S., Orban, M., Cafarello, S. T., Charatsidou, I., Poźniak, J., Dehairs, J., Vanheer, L., Pulido-Vicuña, C. A., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0415 · Cited by 24
Motlova, L., Šnajdr, I., Kutil, Z., Andris, E., Ptáček, J., Novotná, A., Nováková, Z., Havlínová, B., TUECKMANTEL, W., Draberova, H., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00212 · Cited by 21
Wu, C., Lusvarghi, S., Wang, J.-C., Hsiao, S.-H., Huang, Y.-H., Hung, T., & Ambudkar, S. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010238 · Cited by 20
“reported that TMP195 can suppress breast cancer growth and metastasis by genomic reprogramming of monocytes and macrophages into tumoricidal cells [22].”
BackgroundTumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies
Ma, Y., Sun, Y., Guo, H., & Yang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418131 · Cited by 28
Engineering multi-specific nano-antibodies for cancer immunotherapy
Fan, Y.-N., Zhu, L., Qing, Y.-X., Ye, S.-Y., Ye, Q., Huang, X., Zhao, D., Tian, T.-Y., Li, F.-C., Yan, G.-R., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01425-5 · Cited by 28
Tang, C. C., Du, Y., Liang, Q. Y., Cheng, Z., & Tian, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00383e · Cited by 21
Huang, R., Zeng, Z., Li, G., Song, D., Yan, P., Yin, H., Hu, P., Zhu, X., Chang, R., Zhang, X., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00828 · Cited by 23
Pharmacogenomics for immunotherapy and immune-related cardiotoxicity
Lal, J. C., Eng, C., & Cheng, F. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa137 · Cited by 25
“Specifically, a novel Class IIa HDAC inhibitor was previously reported to play a direct role in polarizing macrophages to highly phagocytic and pro-inflammatory phenotype and synergized with anti-PD1 treatment in a breast cancer model resistant to ICB monotherapy (60).”
BackgroundRole of Histone Deacetylases in Monocyte Function in Health and Chronic Inflammatory Diseases
Tordera, R. M., & Cortés-Erice, M. (2021) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2021_59 · Cited by 21
Expression of O-glycosylated oncofetal fibronectin in alternatively activated human macrophages
Santos, M. A. R. D. C., dos Reis, J. S., Santos, C. A. D. N., da Costa, K. M., Barcelos, P. M., Francisco, K. Q. D. O., Barbosa, P. A. G. N., da Silva, E. D. S., Freire-de-Lima, C. G., Morrot, A., et al. (2022) · Immunologic Research · doi:10.1007/s12026-022-09321-9 · Cited by 20
Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms
Mukherjee, A., Zamani, F., & Suzuki, T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01160 · Cited by 24
The Roles and Targeting of Tumor-Associated Macrophages
Li, Y., Wang, R., & Gao, Q. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2809207 · Cited by 22
“cer TME, enhanced their phagocytic activity, and reduced tumor burden and lung metastases [58].”
BackgroundThe cross-talk between macrophages and tumor cells as a target for cancer treatment
Aizaz, M., Khan, A. U., Khan, F., Khan, M., Saleh, E. A. M., Nisar, M., & Baran, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1259034 · Cited by 25
Salmaninejad, A., Layeghi, S. M., Falakian, Z., Golestani, S., Kobravi, S., Talebi, S., & Yousefi, M. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01417-w · Cited by 25
“This was already shown for TMP195, a selective class IIa histone deacetylase (HDACIIa) inhibitor that reprograms TAMs toward M1-like phenotypes, decreases tumor burden, and enhances antitumor effects in MMTV-PyMT mice, especially when combined with paclitaxel [156, 159].”
BackgroundLai, L., Cheng, P., Yan, M., Gu, Y., & Xue, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9781 · Cited by 26
Jairath, N. K., Farha, M. W., Srinivasan, S., Jairath, R., Green, M. D., Dess, R. T., Jackson, W., Weiner, A. B., Schaeffer, E. M., Zhao, S. G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061973 · Cited by 18
“For this reason, TAMs have been an attractive target of therapy in cancer patients, and strategies to deplete these cell populations have been investigated in the clinical setting [31,39,40].”
Downregulation of nc886 contributes to prostate cancer cell invasion and TGFβ1-induced EMT
Yang, R., Zuo, L., Ma, H., Zhou, Y., Zhou, P., Wang, L., Wang, M., Latif, M., & Kong, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2020.12.010 · Cited by 18
“Most cellular protein degradation is subject to the ubiquitin-proteasome system control.(34) Increasing evidence highlights a role for UPS control in the regulation of SNAIL activity.”
BackgroundLal, J. C., Townsend, M. G., Mehta, A. K., Oliwa, M., Miller, E., Sotayo, A. O., Cheney, E. M., Mittendorf, E. A., Letai, A. G., & Guerriero, J. L. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01448-1 · Cited by 24
Self-citationSubverted macrophages in the triple-negative breast cancer ecosystem
Shang, L., Zhong, Y., Yao, Y., Liu, C., Wang, L., Zhang, W., Liu, J., Wang, X., & Sun, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115414 · Cited by 23
Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing
Zins, K., & Abraham, D. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_17 · Cited by 24
Polarization of M2 Tumor-Associated Macrophages (TAMs) in Cancer Immunotherapy
Bui, I., & Bonavida, B. (2024) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2024053830 · Cited by 20
Qu, Y., Chen, C., Sun, F., Liu, S., Zhao, G., Zhao, Z., Liu, C., Jiang, X., & Li, T. (2025) · Nature Communications · doi:10.1038/s41467-025-61974-w · Cited by 20
“TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory M Φ s within tumors by modifying epigenetic signatures and remodeling the TME 33 – 35 .”
Inflammation awakens dormant cancer cells by modulating the epithelial–mesenchymal phenotypic state
Zhang, J., Zhang, J., Han, L., Wu, S., Li, J., Eaton, E. N., Yuan, B., Reinhardt, F., Li, H., Strasser, P. C., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515009122 · Cited by 29
“This depletion was achieved experimentally by administration of a monoclonal antibody reactive with murine CSF - 1, the factor that serves to recruit and then differentiate macrophages, which was applied together with clodronate liposomes, which serves to deplete phagocytic cells ( 36 , 37 ).”
Turkman, N., Liu, D., & Pirola, I. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114011 · Cited by 18
Ge, Z., Wu, S., Qi, Z., & Ding, S. (2022) · Journal of Cancer · doi:10.7150/jca.76136 · Cited by 18
“Of note, M2-to-M1 repolarization of TAMs can restore the anti-tumor effects of TAMs [10, 11].”
BackgroundPhoton- and Proton-Mediated Biological Effects: What Has Been Learned?
Jumaniyazova, E. D., Смык, Д., Vishnyakova, P., Fatkhudinov, T., & Gordon, K. B. (2022) · Life · doi:10.3390/life13010030 · Cited by 19
“Tumor cells exhibit a capacity to recruit monocytes from peripheral blood and ensure their activation into tumor-supporting phenotypes [20,21].”
BackgroundMajid, U., Bergsland, C. H., Sveen, A., Bruun, J., Eilertsen, I. A., Bækkevold, E. S., Nesbakken, A., Yaqub, S., Jahnsen, F. L., & Lothe, R. A. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00926-w · Cited by 22
“Furthermore, pharmacological activation of TAMs can drive potent anti-tumor immunity together with activated CD8 + T cells in mouse models [16, 17].”
Guillebon, É. D., Jimenez, M., Mazzarella, L., Betsou, F., Stadler, P. F., Peták, I., Jeannot, E., Chanas, L., Servant, N., Marret, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100106 · Cited by 23
“Finally, HDACi have been shown to decrease MDSC, increase natural killer (NK) cell proliferation and reprogram macrophages toward an M1 antitumor phenotype.(48) Effects of HDAC inhibition on innate and adaptive immune responses are summarized in Figure 1.”
BackgroundZhao, Y., Pei, L., Liu, B., Mao, Z., Niu, Y., Li, S., Yang, M., Liu, W., Hai, H., Luo, Y., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00950 · Cited by 22
Chang, T. C., Matossian, M. D., Elliott, S. G., Burks, H. E., Sabol, R. A., Uçar, D. A., Wathieu, H., Zabaleta, J., Valle, L. D., Gill, S. K., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226464 · Cited by 18
“DACi have emerged as an effective targeted therapy in breast carcinomas in preclinical studies [32], specifically in TNBC subtypes [33].”
BackgroundImaging and therapeutic targeting of the tumor immune microenvironment with biologics
Arnouk, S. M., Groof, T. W. M. D., & Ginderachter, J. A. V. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114239 · Cited by 17
The role of class IIa histone deacetylases in regulating endothelial function
Shen, Z., Bei, Y., Lin, H., Wei, T.-F., Dai, Y., Hu, Y., Zhang, C., & Dai, H. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1091794 · Cited by 19
“Class IIa HDAC inhibitors also showed strong antitumor effects by altering the tumor microenvironment and enhancing cell death (Kikuchi et al., 2015; Guerriero et al., 2017).”
BackgroundEpigenetic modulations of immune cells: from normal development to tumor progression
Xu, Y., He, Z., Du, J., Chen, K., Creemers, J. W. M., Wang, B., Fan, L., & Wang, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.88327 · Cited by 23
“Similarly, in a macrophage-dependent autochthonous mouse model of breast cancer, Guerriero et al. demonstrated that TMP195, a selective class IIa HDAC inhibitor, reduces tumor burden and pulmonary metastases by mediating macrophage phenotypes (173).”
BackgroundPD-1/PD-L1 blockade in paediatric cancers: What does the future hold?
Moreno-Vicente, J., Beers, S. A., & Gray, J. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.025 · Cited by 16
Qin, X., Xu, Y., Peng, S., Qian, S., Zhang, X., Shen, S., Yang, J., & Ye, J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.133 · Cited by 17
Wang, J., Zhang, Q., Li, Q., Mu, Y., Jing, J., Li, W., Li, W., Wang, J., Yu, G., Wang, X., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00823-4 · Cited by 18
Blanquart, C., Linot, C., Cartron, P., Tomaselli, D., Mai, A., & Bertrand, P. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180706105903 · Cited by 19
Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective
Bleve, A., Consonni, F. M., Porta, C., Garlatti, V., & Sica, A. (2022) · Cancers · doi:10.3390/cancers14030510 · Cited by 22
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 23
The portrayal of macrophages as tools and targets: A paradigm shift in cancer management
Jain, N., Srinivasarao, D. A., Famta, P., Shah, S., Vambhurkar, G. B., Shahrukh, S., Singh, S. B., & Srivastava, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121399 · Cited by 17
Nanoparticle-Based Immunotherapy for Reversing T-Cell Exhaustion
Li, F., Wang, Y. J., Chen, D., & Du, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031396 · Cited by 21
“Furthermore, the combination of TMP195 and anti-PD-1 has exhibited additive effects on anti-tumor effects [148].”
BackgroundWang, H., Lou, J., Liu, H., Liu, Y., Xie, B., Zhang, W., Xie, J., Pan, H., & Han, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-66388-0 · Cited by 20
“Class IIa histone deacetylase (HDAC) inhibitors can reprogram TAMs in breast cancer, leading to an anti-tumor effect and improved efficacy of chemotherapy and immunotherapy 25 .”
BackgroundZhang, W., Ge, L., Zhang, Y., Zhang, Z., Zhang, W., Song, F., Huang, P., & Xu, T. (2025) · European journal of medical research · doi:10.1186/s40001-025-02326-8 · Cited by 25
Immunocyte‐Derived Nanodrugs for Cancer Therapy
Zhu, X., Wang, T., Jia, H., & Wu, F. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202207181 · Cited by 17
Yang, F., Sun, S., Wang, C., Haas, M., Yeo, S. K., & Guan, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0839-1 · Cited by 16
Chen, C., Sang, Y., Liu, L., Feng, Z., Liang, Z., & Pei, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s208908 · Cited by 16
“The epigenetic regulation of gene expression plays a crucial role in the progression of cancers, including lung cancer,(34) and histone acetylation plays a key role in gene transcriptional regulation.(35,36) Acetylation neutralizes the positive charge of histone lysine residues, producing a related chromatin conformat…”
BackgroundCo-dependencies in the tumor immune microenvironment
Chen, P., & Dey, P. (2022) · Oncogene · doi:10.1038/s41388-022-02406-7 · Cited by 15
“, HDAC inhibition) of macrophages have been shown to improve the effectiveness of ICIs (including anti-PD-1/PD-L1 or anti-CTLA-4) in a variety of mouse models, including Kras-mutated PDAC [111], Braf-mutated melanoma [112, 113], MMTV-PyMT breast cancer [114].”
BackgroundEngineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential
Chamorro, D. F., Somes, L. K., & Hoyos, V. (2023) · Cancers · doi:10.3390/cancers16010124 · Cited by 25
“Other potential therapeutic avenues to target TAMs in the breast TME include depletion via CSF-1/CSF1R inhibition [172–175], modulation via class IIa HDAC inhibition [176], and reprogramming via antibodies targeting the pattern recognition scavenger receptor MARCO [177].”
BackgroundHDAC7: a promising target in cancer
Liu, C., Zheng, D., Pu, X., & Li, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1327933 · Cited by 24
“Additionally, TMP195 demonstrated ef fi cacy in reducing breast tumors and metastases in mice through the recruitment and differentiation of anti-tumor macrophages (83).”
BackgroundBio-Responsive nanoparticle for tumor targeting and enhanced photo-immunotherapy
Tian, D., Qin, F., Zhao, H., Zhang, C., Wang, H., Liu, N., & Ai, Y. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111681 · Cited by 16
Immunomodulation: An immune regulatory mechanism in carcinoma therapeutics
Alsaffar, R. M., Ali, S., Rashid, S., Rashid, S. M., Majid, S., & Rehman, M. U. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107984 · Cited by 16
Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
Mao, Y., Wang, X., Chen, C., Zhao, Q., Liu, Y., Zhang, J., & Wang, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.018 · Cited by 15
Histone acetylation modulators in breast cancer
Yuan, X., & Rosen, J. M. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02006-9 · Cited by 16
Costanzo, G., Buccheri, R., Cosentino, G., Reale, C., Zuccalà, S., Marrazzo, A., Amata, E., Rescifina, A., & Pasquinucci, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117998 · Cited by 15
Fu, X., Pang, M., Wang, Z., & Wang, H. (2025) · Cancer Control · doi:10.1177/10732748251406674 · Cited by 23
“219,220 In HCC samples with normal or elevated serum CA19-9 levels, elevated CA19-9 levels correlate with increased M2 macrophage levels.”
Toghraie, F. S., Bayat, M., Hosseini, M. S., & Ramezani, A. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01051-y · Cited by 25
Tumor-Associated Macrophages—Implications for Molecular Oncology and Imaging
Kimm, M. A., Klenk, C., Alunni‐Fabbroni, M., Kästle, S., Stechele, M., Ricke, J., Eisenblätter, M., & Wildgruber, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040374 · Cited by 20
“CCCR2-CCL2 inhibition [183–185] Trabectedin [186,187] Class IIa HDAC inhibitors [188,189] CXCR4-CXCL12 inhibition [190] Biphosphonates [121,191] CD40 agonists [192,193] Anti-CSF-1R [194,195] PI3Kγ inhibitors [196] SIRPα inhibitors [197,198] STAB1 inhibitors [199] Checkpoint inhibitors [200] TLRs agonists [201] siRNA/m…”
BackgroundTurkman, N., Liu, D., & Pirola, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-90069-x · Cited by 13
Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells
Vidana Gamage, H. E., Albright, S. T., Smith, A. J., Farmer, R., Shahoei, S. H., Wang, Y., Fink, E. C., Jacquin, E., Weisser, E., Bautista, R. O., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217086 · Cited by 13
“Therefore, it is now appreciated that rather than just eliminating or inhibiting myeloid cells, strategies are required to ‘re-educate’ myeloid cells away from being pro-tumorigenic and towards being anti-tumorigenic [6–8].”
Jin, Y., Qi, X., Yu, X., Cheng, X., Chen, B., Wu, M., Zhang, J., Yin, H., Lu, Y., Zhou, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.01.021 · Cited by 15
“…identified as a potential therapeutic target for various diseases, including autoimmune diseases like Crohn’s disease 9,10 , solid tumors like non-small-cell lung cancer 11-15 , and notably, hematologic malignancies like diffuse large B cell lymphoma (DLBCL) and acute myeloid leukemia (AML) 16-18 .”
Novel Therapeutic Strategies for Solid Tumor Based on Body’s Intrinsic Antitumor Immune System
Duan, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489979 · Cited by 14
Salah, A., Li, Y., Wang, H., Qi, N., & Wu, Y. (2021) · DNA and Cell Biology · doi:10.1089/dna.2020.6087 · Cited by 14
“Injected TMP195 into a mouse model of breast cancer led to increased recruited and differentiated M1 M f s to the tumor site, boosting the anti-tumor potential of M f s (Guerriero et al. , 2017).”
Ito, R., Miyanishi, K., Kubo, T., Hamaguchi, K., Osuga, T., Tanaka, S., Ohnuma, H., Murase, K., Takada, K., Nagayama, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10484-2 · Cited by 14
“Lenvatinib and vehicle (HCl) were administered as a once-daily oral dose, and TMP269 and vehicle (DMSO), intraperitoneally once-daily for 21 days, as previously described [14, 15].”
MethodMacrophage Origin, Metabolic Reprogramming and IL-1β Signaling: Promises and Pitfalls in Lung Cancer
Guilbaud, E., Gautier, E. L., & Yvan‐Charvet, L. (2019) · Cancers · doi:10.3390/cancers11030298 · Cited by 19
“In line with these observations, checkpoint blockade therapy to restore immune cell nutrition restriction, nutritional intervention or treatment with a histone deacetylase inhibitor (TMP195) converted immune cells to an antitumor phenotype in mouse models of cancer metastasis (Figure 3) [153,160–162] including a shift…”
BackgroundAghamajidi, A., Farhangnia, P., Pashangzadeh, S., Damavandi, A. R., & Jafari, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02727-3 · Cited by 12
“TMP195, an HDAC Class IIa inhibitor, may transform tumor-infiltrating monocytes and macrophages into cells able to sustain a robust CD8+ T-cell-mediated anti-tumor immune response in breast cancer and reduce metastasis [115, 116].”
BackgroundMolecular origin and biological effects of exercise mimetics
Zhu, Y., & Song, G. (2023) · Journal of Exercise Science & Fitness · doi:10.1016/j.jesf.2023.12.002 · Cited by 17
“…(HAT) activity or inhibiting histone deacetylase (HDAC) activity can promote histone acetylation, thereby activating chromatin, promoting gene expression and translation, and participating in the regulation of immune function, 108 cardiovascular function, 109 and nervous system function.”
BackgroundClass IIa HDACs inhibitor TMP269 promotes M1 polarization of macrophages after spinal cord injury
Qi, X., & Wang, P. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26446 · Cited by 13
“One recent research has reported that the inhibition of class IIa HDAC reduces the proliferation and metastases of breast tumors through acting on anti-tumor macrophages.(19) Given that class IIa HDACs may exert an anti-inflammatory activity in macrophages, we assume that whether these enzymes would participate in mac…”
BackgroundZhao, G., Jia, J., Wang, L., Zhang, Y., Yang, H., Lü, Y., Yu, R., Liu, H., & Zhu, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s273527 · Cited by 12
Chen, C., LIM, D. J., Cai, Z., Zhang, F., Liu, G., Dong, C., & Feng, Z. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113783 · Cited by 12
Zhang, J., Su, Y., Wang, X., Yao, X., & Du, J. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2001 · Cited by 17
Huang, A., Guo, F., Yu, Z., Liu, P., Dong, S., Zhang, Y., Kong, Y., Kong, X., Li, T., Luo, Y., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19769 · Cited by 12
Shettigar, A., Salunke, R., Modi, D. N., & Mukherjee, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110250 · Cited by 12
HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients
Burgess, M. L., Chen, Y.-C. E., Mapp, S., Blumenthal, A., Mollee, P. N., Gill, D. S., & Saunders, N. A. (2020) · Oncogene · doi:10.1038/s41388-020-01394-w · Cited by 12
Epigenetic modulation: Research progress on histone acetylation levels in major depressive disorders
Meng, Y., Du, J., Liu, N., Qiang, Y., Xiao, L., Lan, X., Ma, L., Yang, J.-M., Yu, J., & Lu, G. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2125978 · Cited by 14
“Histone acetylation is involved in the pathogenesis of various diseases such as cancer [58, 59], neurodegenerative diseases [60], and depression [30].”
BackgroundImproving efficacy of cancer immunotherapy through targeting of macrophages
Peranzoni, E., & Donnadieu, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1515447 · Cited by 12
Wei, C., Hu, S., Luo, M., Chen, C., Wang, W., Zhang, W., & Zhou, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682436 · Cited by 10
“found that the HDAC inhibitor TMP195 promotes macrophage differentiation toward an anti-tumor phenotype in mouse models of breast cancer (4).”
BackgroundPeng, Z., Zhao, Q., Tian, X., Lei, T., Xiang, R., Chen, L., & Yang, Y. (2022) · Molecular Informatics · doi:10.1002/minf.202100295 · Cited by 11
How to use macrophages to realise the treatment of tumour
Zhang, X., Li, W., Sun, J., Yang, Z., Guan, Q., Wang, R., Li, X., Li, Y., Feng, Y., & Wang, Y. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1775236 · Cited by 10
Holterhus, M., Altvater, B., Kailayangiri, S., & Rössig, C. (2022) · Cancers · doi:10.3390/cancers14092177 · Cited by 11
Arylamine N-acetyltransferase 1 activity is regulated by the protein acetylation status
Salazar-González, R. A., Doll, M. A., & Hein, D. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.797469 · Cited by 9
Blanc, F., Bertho, N., Piton, G., Leplat, J. J. J. J., Egidy, G., Bourneuf, E., Vincent-Naulleau, S. S., & Prévost‐Blondel, A. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03503-6 · Cited by 11
“For instance, TAMs can switch from pro-tumoral to anti-tumoral status and cooperate with TILs leading to reduced tumor burden after STING/Type 1 IFN activation or inhibition of Class IIa HDAC or Clever-1 [42–44].”
BackgroundBiswas, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375528 · Cited by 11
Höppner, J., Firat, D., Parvez-Khan, M., Reyes, M., Hanna, P., Yadav, P. S., Dean, T., Ramos‐Torres, K. M., Brugarolas, P., Collins, M. T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500176122 · Cited by 9
“Nevertheless, class IIa HDAC inhibitors have been developed ( 53 , 54 ) and could prove helpful, for example, in further assessing the underlying disease mechanisms in the current T410R mice.”
Haloui, R., Elkhattabi, K., Mkhayar, K., Daouı, O., Chtita, S., Haoudi-Mazzah, A., & Elkhattabi, S. (2023) · Scientific African · doi:10.1016/j.sciaf.2023.e01990 · Cited by 11
Gagliano, T., Kerschbamer, E., Baccarani, U., Minisini, M., Giorgio, E. D., Dalla, E., Weichenberger, C. X., Cherchi, V. A., Terrosu, G., & Brancolini, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116374 · Cited by 10
“In preclinical models, the efficacy of epigenetic therapy based on HDACIs in affecting the action of immune cells, has been demonstrated even in the case of metastasis [20,21].”
Jing, W., Zhang, L., Qin, F., Li, X., Guo, X., Li, Y., Qiu, C., & Zhao, Y. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.09.006 · Cited by 11
Rodet, F., Capuz, A., Ozcan, B., Beillan, R. L., Raffo‐Romero, A., Kobeissy, F. H., Duhamel, M., & Salzet, M. (2019) · Cells · doi:10.3390/cells8121490 · Cited by 10
“At present one of the main anti-tumoral strategies consists in re-polarizing the TAMs towards a pro-inflammatory phenotype [9,10] in order to boost the immune response in cancer patients.”
Han, X., Du, J., Zheng, Y.-D., Dai, J., Lin, S.-W., Zhang, B., Zhong, F., Lin, Z.-G., Jiang, S., Wei, W., et al. (2021) · BioMed Research International · doi:10.1155/2021/5089371 · Cited by 9
“macrophage phenotypes, including the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors [47].”
BackgroundWaaijer, S. J. H., Suurs, F. V., Hau, C., Vrijland, K., de Visser, K. E., de Groot, D. J. A., de Vries, E. G. E., Hooge, M. N. L., & Schroder, C. P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.786191 · Cited by 8
Asad, S., Damicis, A., Heng, Y. J., Kananen, K., Collier, K. A., Adams, E., Kensler, K. H., Baker, G. M., Wesolowski, R., Sardesai, S. D., et al. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01573-5 · Cited by 13
Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells
Bendre, S. V., Wang, Y., Hajyousif, B., K C, R., Bhogale, S. G., Pradeep, D., Krawczynska, N., Schane, C. P., Weisser, E., Singh, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.adx5490 · Cited by 8
“Therefore, rather than ablating or inhibiting their activities altogether, efforts to reeducate MCs toward antitumor phenotypes are likely to have substantial clinical benefit ( 19 – 21 ).”
Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
Small, S. H., Numan, Y., & Platanias, L. C. (2021) · Biomedicines · doi:10.3390/biomedicines9111631 · Cited by 9
“Additionally, in another preclinical study, an HDAC inhibitor that induces macrophages, to assume an M1-like phenotype, causes tumor regression in a macrophage-dependent manner [39].”
BackgroundSheban, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183578 · Cited by 11
“The inhibitor of HDAC, TMP195, was shown to alter the TME and reduce tumor growth and pulmonary metastases by modulating the phenotype of TAMs.”
BackgroundGenetic and epigenetic strategies for advancing ovarian cancer immunotherapy
Cho, Y., Milane, L. S., & Amiji, M. M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1602605 · Cited by 7
“TMP195 treatment in vivo led to the alteration of TAMs and reduction of tumor burden and metastases [105].”
BackgroundResultMacrophage imaging and subset analysis using single-cell RNA sequencing
Arlauckas, S. P., Oh, N., Li, R., Weissleder, R., & Miller, M. A. (2020) · Nanotheranostics · doi:10.7150/ntno.50185 · Cited by 8
“[85] Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S et”
BackgroundNovel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
Ozaniak, A., Vachtenheim, J., Lischke, R., Bartůňková, J., & Strizova, Z. O. (2021) · Biomedicines · doi:10.3390/biomedicines9080935 · Cited by 8
“Even though TAMs mainly exploit protumorigenic mechanisms, several antitumor functions of TAMs have also been reported [102].”
BackgroundTeng, L., Li, Z., Shi, Y., Gao, Z., Yang, Y., Wang, Y., & Bi, L. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101547 · Cited by 8
Valproic Acid Regulates HR and Cell Cycle Through MUS81-pRPA2 Pathway in Response to Hydroxyurea
Su, B., LIM, D. J., Tian, Z., Liu, G., Ding, C., Cai, Z., Chen, C., Zhang, F., & Feng, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681278 · Cited by 8
“Recently, it was reported that TMP195, a class IIa HDACi, altered the tumor microenvironment and reduced tumor burden and pulmonary metastases by recruiting macrophages to tumor sites (50), we hypothesized that VPA might regulate macrophages recruitment in breast cancer metastasis.”
BackgroundStylianou, M., Kisby, T., Despotopoulou, D., Parker, H., Thawley, A., Arashvand, K., Lozano, N., MacDonald, A. S., & Kostarelos, K. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102342 · Cited by 9
Metadata
- Authors
- Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., Davis, S. P., Lobera, M., Nolan, M. A., & Letai, A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Nolan, Michael A.
- Letai, Anthony
- ORCID
- Venue
- Nature
- Published
- 2017-03
- Volume
- 543
- Issue
- 7645
- Pages
- 428-432
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8170529
- OpenAlex
- W2591627715
- Cited by
- 558
- References
- 35
- Citations by year
- 2026: 35 · 2025: 51 · 2024: 51 · 2023: 63 · 2022: 74 · 2021: 94 · 2020: 68 · 2019: 63 · 2018: 33 · 2017: 25
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA205967, F32CA180733)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- breast cancer, tumour-associated macrophages, antitumor immunity, tumor microenvironment, lung metastasis, chemotherapy synergy, T cell checkpoint blockade, CSF-1
- MeSH terms
- Animals, Benzamides, Breast Neoplasms, Cell Differentiation, Disease Models, Animal, Drug Synergism, Female, Humans, Lung Neoplasms, Macrophage Activation, Macrophages, Oxadiazoles, Phagocytosis, Cell Line, Tumor, Tumor Burden, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.